FemasysFEMY -4.16%55 Return-on-Tangible-Equity is 52.47% as of Mar. 2026. GuruFocus rates FEMY with a GF Score™ of 55/100 and a GF Value™ of $12.17 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 759 Medical Devices & Instruments companies, Femasys ranks worse than 95.26% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Femasys's annualized net income for the quarter that ended in Mar. 2026 was $3.38 Mil. Femasys's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $6.45 Mil. Therefore, Femasys's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 52.47%.
The historical rank and industry rank for Femasys's Return-on-Tangible-Equity or its related term are showing as below:
FEMY'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -467.34 Med: -133.8 Max: -54.85
Current: -286.87
During the past 7 years, Femasys's highest Return-on-Tangible-Equity was -54.85%. The lowest was -467.34%. And the median was -133.80%.
FEMY's Return-on-Tangible-Equity is ranked worse than 95.26% of 759
companies
in the Medical Devices & Instruments industry
Industry Median: 4.07
vs FEMY: -286.87
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Femasys Return-on-Tangible-Equity Related Terms
Femasys Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Femasys's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FEMY vs UEEC, BNGO, CUPR: Return-on-Tangible-Equity Comparison
For the Medical Instruments & Supplies subindustry, Femasys's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Femasys Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Femasys's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Femasys's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 52.47% mean?
Femasys (FEMY) has a Return-on-Tangible-Equity of 52.47% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Femasys and its competitors. According to the industry distribution chart, Femasys ranks #723 out of 759 companies in the Medical Devices & Instruments industry, placing it in the top 95.3%.
Is Femasys' Return-on-Tangible-Equity too high?
Femasys' current Return-on-Tangible-Equity is 52.47%. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.07. Femasys' value of 52.47% is 1189.2% above this industry median. Based on the distribution chart, Femasys ranks #723 out of 759 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Femasys has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Femasys' Return-on-Tangible-Equity compare to UEEC and BNGO?
According to the Medical Devices & Instruments industry distribution chart, Femasys ranks #723 out of 759 companies for Return-on-Tangible-Equity. This places Femasys in the lower half of its industry. The industry median Return-on-Tangible-Equity is 4.07. Femasys' value of 52.47% is 1189.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.07, based on 759 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Femasys's current Return-on-Tangible-Equity of 52.47% is 1189.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Femasys and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Femasys's current Return-on-Tangible-Equity is 52.47%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Femasys stock overvalued right now?
Based on GuruFocus' analysis, Femasys (FEMY) is currently considered Possible Value Trap. The stock's GF Value™ is $12.17, compared to a current price of $4.17 — trading 65.7% below its estimated fair value. The current Return-on-Tangible-Equity is 52.47% and 1189.2% above the Medical Devices & Instruments industry median of 4.07. Femasys' overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Femasys (FEMY), the current Return-on-Tangible-Equity is 52.47% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Femasys (FEMY) Overvalued in 2026?
Based on GuruFocus' analysis, Femasys stock appears to be undervalued.
The current stock price of $4.17 is trading 65.7% below its estimated GF Value™ of $12.17.
GuruFocus considers Femasys to be Possible Value Trap.
Key valuation signals for FEMY:
Return-on-Tangible-Equity: 52.47%
GF Value™: $12.17 vs. price of $4.17 (65.7% below fair value)
Industry Position: 1189.2% above the Medical Devices & Instruments median (#723 of 759)
No single metric tells the full story. See the FEMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
55GF Score
Get the complete analysis for FEMY
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FEMY has been successfully added to your 
